188 related articles for article (PubMed ID: 36348153)
21. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.
Luo Z; Gyawali B; Han S; Shi L; Guan X; Wagner AK
Semin Oncol; 2021 Apr; 48(2):141-144. PubMed ID: 33875231
[TBL] [Abstract][Full Text] [Related]
22. Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness.
Hernandez I; Cousin EM; Wouters OJ; Gabriel N; Cameron T; Sullivan SD
J Manag Care Spec Pharm; 2024 Mar; 30(3):218-225. PubMed ID: 38088899
[TBL] [Abstract][Full Text] [Related]
23. Striving for affordable medicine: Lessons in price negotiation learned from the United Kingdom.
McKeown S
J Manag Care Spec Pharm; 2024 Mar; 30(3):259-264. PubMed ID: 38241261
[TBL] [Abstract][Full Text] [Related]
24. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
25. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
26. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
Johnson M; Kishore S; Nayak RK; Dusetzina SB
Curr Cardiol Rep; 2023 Jun; 25(6):577-581. PubMed ID: 37097432
[TBL] [Abstract][Full Text] [Related]
27. Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act's Medicare Drug Price Negotiation Program.
Poudel N; Ngorsuraches S
J Manag Care Spec Pharm; 2024 Mar; 30(3):241-246. PubMed ID: 38140902
[TBL] [Abstract][Full Text] [Related]
28. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
Radic D; Haugk S; Radic M
Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
[TBL] [Abstract][Full Text] [Related]
29. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
[TBL] [Abstract][Full Text] [Related]
30. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act.
Vogel M; Kakani P; Chandra A; Conti RM
Nat Biotechnol; 2024 Mar; 42(3):406-412. PubMed ID: 38297186
[TBL] [Abstract][Full Text] [Related]
31. Common Pharmaceutical Price and Cost Controls in the United Kingdom, France, and Germany: Lessons for the United States.
Rodwin MA
Int J Health Serv; 2021 Jul; 51(3):379-391. PubMed ID: 33686883
[TBL] [Abstract][Full Text] [Related]
32. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
Rand LZ; Kesselheim AS
J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
[TBL] [Abstract][Full Text] [Related]
33. Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations?
Horn DM; Jacobson M; Alpert AE; Duggan MG
JCO Oncol Pract; 2024 Feb; 20(2):254-261. PubMed ID: 38060993
[TBL] [Abstract][Full Text] [Related]
34. How Medicare could get better prices on prescription drugs.
Outterson K; Kesselheim AS
Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
[TBL] [Abstract][Full Text] [Related]
35. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
Academy of Managed Care Pharmacy
J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
[TBL] [Abstract][Full Text] [Related]
36. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
Rawson NSB
Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
[TBL] [Abstract][Full Text] [Related]
37. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation.
Vogel M; Zhao O; Feldman WB; Chandra A; Kesselheim AS; Rome BN
JAMA Intern Med; 2024 Jan; 184(1):63-69. PubMed ID: 38010643
[TBL] [Abstract][Full Text] [Related]
38. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
39. AMCP Guide to Pharmaceutical Payment Methods.
AMCP Task Force on Drug Payment Methodologies
J Manag Care Pharm; 2007 Oct; 13(8 Suppl C):S1-39. PubMed ID: 17970611
[TBL] [Abstract][Full Text] [Related]
40. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
Henschke C; Sundmacher L; Busse R
Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
